Physician profile
Abdulla Majid-Moosa
NPI 1558628859
$202,057.26
in general payments reported to CMS, 2019-2025
33 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $315 · 2021: $1,409 · 2022: $5,303 · 2023: $73K · 2024: $55K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $128K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $24K · Food and Beverage: $13K · Consulting Fee: $800 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $128,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,950.00 |
| Travel and Lodging | $23,575.34 |
| Food and Beverage | $13,372.81 |
| Consulting Fee | $800.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $195,537.26 | 2021-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Pulmonx Corporation | $2,724.86 | 2021-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Glaxosmithkline, LLC. | $1,338.61 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $511.42 | 2024-2025 | |
| Merit Medical Systems INC | $461.23 | 2023 | Aero Stent and Delivery System, Aeromini Stent and Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.64 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $135.67 | 2019-2023 | Imfinzi, Fasenra |
| Merck Sharp & Dohme LLC | $108.68 | 2022-2025 | Keytruda, Recarbrio, Zerbaxa |
| Janssen Pharmaceuticals, INC | $108.31 | 2022-2023 | Xarelto |
| Mylan Specialty L.P. | $102.42 | 2021-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $84.77 | 2022-2023 | Uptravi |
| United Therapeutics Corporation | $70.37 | 2021-2023 | Tyvaso |
| Electromed, INC. | $65.15 | 2024-2025 | Smartvest |
| E.R. Squibb & Sons, L.L.C. | $51.85 | 2019-2023 | |
| Steris Corporation | $51.35 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $48.82 | 2019-2024 | Giapreza |
| Paratek Pharmaceuticals, INC. | $46.13 | 2022-2023 | Nuzyra |
| Viatris Specialty LLC | $43.49 | 2025 | Yupelri |
| Ucb, INC. | $40.22 | 2022 | |
| Atricure, INC. | $37.57 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $34.80 | 2023 | Dupixent |
| Olympus America INC. | $33.36 | 2025 | |
| Partner Therapeutics, INC. | $32.50 | 2025 | Bizengri |
| Tactile Systems Technology INC | $31.57 | 2023 | Flexitouch Plus, Entre Plus |
| Ani Pharmaceuticals, INC. | $30.64 | 2025 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $29.98 | 2023 | |
| Abbvie INC. | $28.97 | 2025 | |
| Mallinckrodt Enterprises LLC | $27.88 | 2019 | |
| Innovation Technologies INC | $22.96 | 2024 | Irrisept |
| Grifols USA, LLC | $22.47 | 2024 | Prolastin-C Liquid |
| Davol INC. | $19.23 | 2025 | Arista |
| Chiesi USA, INC. | $16.27 | 2020 | |
| Pfizer INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdulla Majid-Moosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.